%0 Generic
%A Cardoso, F.
%A Juric, D.
%A Lerebours, F.
%A Krop, I.
%A Borrego, M. Ruiz
%A Neven, P.
%A Park, Y. H.
%A Yardley, D.
%A Jhaveri, K.
%A Arce, C.
%A Gu, E.
%A Akdere, M.
%A Rugo, H. S.
%T Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
%D 2022
%@ 0923-7534
%U http://hdl.handle.net/10668/21904
%~